May 1, 2009EuroIntervention
PRO-Kinetic: results from an “all-comers” single centre clinical experience
Key result
PRO-Kinetic stent linked to an 8.7% MACE rate at six months in real-world patients.
- n=515
Population
515 consecutive "real world" patients treated for 540 lesions with either stable or unstable clinical…
Design
Cohort
Follow-up
six months
Authors
Discussion
Loading...
Member takes
Implication
Low 6-month MACE in high-risk real-world patients supports thin-strut BMS role; leaves open randomized comparisons to contemporary DES.
Study Design
Type
Observational (n=515)
Multicenter
No
Structured PICO
P
Population
515 consecutive coronary patients with stable or unstable clinical scenarios treated with the PRO-Kinetic stent, followed for six months.
E
Exposure
PRO-Kinetic stent (non-DES platform)
O
Outcome
MACE rate at six monthscomposite
The PRO-Kinetic bare-metal stent demonstrated an 8.7% MACE rate at 6 months in a real-world, all-comers registry, supporting its viability as a non-DES platform.
Cite This Study
Kornowski et al. (2009) conducted an observational in Coronary artery disease (n=515). PRO-Kinetic stent was evaluated on Major Adverse Cardiac Events (MACE). Treatment with the PRO-Kinetic stent in 515 consecutive real-world coronary patients resulted in a 6-month MACE rate of 8.7% and a stent thrombosis rate of 0.4%.